Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.

ABSTRACT: Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often suboptimal. Individualized combinations are needed in order to attenuate resistance. To help inform selection of safe starting doses for novel, two-agent, targeted drug combinations, we identified clinical trials in adult oncology patients who received targeted drug doublets (PubMed, January 1, 2010 through December 31, 2013). The dose percentage was calculated for each drug: (safe dose in combination divided by single agent full dose) X 100. Additive dose percentage represented the sum of the dose percentage for each drug. A total of 144 studies (N = 8568 patients; 95 combinations) were analyzed. In 51% of trials, each of the two drugs could be administered at 100% of their full dose. The lowest safe addi

SUBMITTER: Liu S 

PROVIDER: S-EPMC4905475 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature